Canaccord Genuity Morning Coffee on Columbia Labs (CBRX) and Watson Pharma (WPI): No Gel For You
CBRX Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Canaccord Genuity Morning Coffee on Columbia Labs (Nasdaq: CBRX) & Watson Pharmaceuticals (NYSE: WPI): No gel for you.
An advisory panel advised the FDA to reject a gel from Columbia Laboratories and Watson Pharmaceuticals, sending shares of the smaller Columbia tumbling on Monday. The gel, Prochieve, was aimed at reducing the risk of premature birth in women with a short cervix who are at higher risk of premature birth. A similar drug called Makena from K-V Pharmaceutical (NYSE: KV-A) is already available in the U.S., and the news sent shares of K-V higher on Monday.
Canaccord Genuity Life Sciences Analyst Randall Stanicky said the panel did not provide the upside surprise for Prochieve, which is disappointing, but he feels it is more than reflected in shares of Watson. He remains bullish on Watson, with his thesis intact despite the news regarding Prochieve. He believes today’s analyst meeting will provide a re-set bar that will leave several triggers to upside including an under-levered balance sheet and appetite for M&A.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
An advisory panel advised the FDA to reject a gel from Columbia Laboratories and Watson Pharmaceuticals, sending shares of the smaller Columbia tumbling on Monday. The gel, Prochieve, was aimed at reducing the risk of premature birth in women with a short cervix who are at higher risk of premature birth. A similar drug called Makena from K-V Pharmaceutical (NYSE: KV-A) is already available in the U.S., and the news sent shares of K-V higher on Monday.
Canaccord Genuity Life Sciences Analyst Randall Stanicky said the panel did not provide the upside surprise for Prochieve, which is disappointing, but he feels it is more than reflected in shares of Watson. He remains bullish on Watson, with his thesis intact despite the news regarding Prochieve. He believes today’s analyst meeting will provide a re-set bar that will leave several triggers to upside including an under-levered balance sheet and appetite for M&A.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
- Canaccord Genuity Maintains a 'Hold' on Urban Outfitters (URBN); Cutting Estimates & Price Target on Weak Sales
- Oppenheimer Reiterates an 'Outperform' on MakeMyTrip (MMYT); Updating Estimates Ahead of March Qtr
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
